Literature DB >> 9578849

Long-term in vivo cochlear transgene expression mediated by recombinant adeno-associated virus.

A Lalwani1, B Walsh, P Reilly, G Carvalho, S Zolotukhin, N Muzyczka, A Mhatre.   

Abstract

Adeno-associated virus (AAV) integrated transgene expression within guinea pig cochlea has been previously documented. This article extends these studies by characterizing the AAV-mediated gene transfer for duration of transgene expression within the cochlea and its effect upon cochlear cytoarchitecture over a period of 6 months. All animals infused with AAV expressed the transgene product, bacterial beta-galactosidase (beta-gal) enzyme, in the spiral limbus, spiral ligament, spiral ganglion cells and the organ of Corti at 2-24 weeks after infusion. However, the level of beta-gal expression, as determined from intensity of immunoreactivity, was relatively lower at 24 weeks as compared with 2 weeks. The cellular and tissue architecture within the AAV-beta-gal perfused cochleae, harvested 2-8 weeks after AAV infusion, was generally intact, ie free from inflammation and cellular degeneration. However, cellular degeneration and degradation was apparent in the cochleae of some but not all animals harvested at 12 and 24 weeks after AAV infusion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578849     DOI: 10.1038/sj.gt.3300573

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

Review 1.  Neurotrophic factors and neural prostheses: potential clinical applications based upon findings in the auditory system.

Authors:  Lisa N Pettingill; Rachael T Richardson; Andrew K Wise; Stephen J O'Leary; Robert K Shepherd
Journal:  IEEE Trans Biomed Eng       Date:  2007-06       Impact factor: 4.538

2.  Surgical method for virally mediated gene delivery to the mouse inner ear through the round window membrane.

Authors:  Omar Akil; Stephanie L Rouse; Dylan K Chan; Lawrence R Lustig
Journal:  J Vis Exp       Date:  2015-03-16       Impact factor: 1.355

3.  Efficient cochlear gene transfection in guinea-pigs with adeno-associated viral vectors by partial digestion of round window membrane.

Authors:  H Wang; R Murphy; D Taaffe; S Yin; L Xia; W W Hauswirth; M Bance; G S Robertson; J Wang
Journal:  Gene Ther       Date:  2011-06-23       Impact factor: 5.250

Review 4.  Nerve maintenance and regeneration in the damaged cochlea.

Authors:  Seiji B Shibata; Cameron L Budenz; Sara A Bowling; Bryan E Pfingst; Yehoash Raphael
Journal:  Hear Res       Date:  2011-05-10       Impact factor: 3.208

Review 5.  The use of neurotrophin therapy in the inner ear to augment cochlear implantation outcomes.

Authors:  Cameron L Budenz; Bryan E Pfingst; Yehoash Raphael
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

6.  Localized cell and drug delivery for auditory prostheses.

Authors:  Jeffrey L Hendricks; Jennifer A Chikar; Mark A Crumling; Yehoash Raphael; David C Martin
Journal:  Hear Res       Date:  2008-06-07       Impact factor: 3.208

7.  [Expression patterns of non-viral transfection with GFP in the organ of Corti in vitro and in vivo. Gene therapy of the inner ear with non-viral vectors].

Authors:  M Praetorius; S Pfannenstiel; C Klingmann; I Baumann; P K Plinkert; H Staecker
Journal:  HNO       Date:  2008-05       Impact factor: 1.284

8.  Functional prestin transduction of immature outer hair cells from normal and prestin-null mice.

Authors:  Anping Xia; Julian R A Wooltorton; Donna J Palmer; Philip Ng; Fred A Pereira; Ruth Anne Eatock; John S Oghalai
Journal:  J Assoc Res Otolaryngol       Date:  2008-05-28

9.  Gene transfer in human vestibular epithelia and the prospects for inner ear gene therapy.

Authors:  Bradley W Kesser; George T Hashisaki; Jeffrey R Holt
Journal:  Laryngoscope       Date:  2008-05       Impact factor: 3.325

10.  Gene transfer using bovine adeno-associated virus in the guinea pig cochlea.

Authors:  S B Shibata; G Di Pasquale; S R Cortez; J A Chiorini; Y Raphael
Journal:  Gene Ther       Date:  2009-05-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.